Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564268 | 1.00 | KMT2A (0.45) | KMT2ACASP3KDM4EALDH1A1BACE1 | |
| SCHEMBL20564085 | 0.96 | KMT2A (0.48) | KMT2ACASP3KDM4EALDH1A1BACE1 | |
| SCHEMBL20564084 | 0.96 | KMT2A (0.48) | KMT2ACASP3KDM4EALDH1A1BACE1 | |
| SCHEMBL20564114 | 0.95 | KMT2A (0.43) | KMT2ACASP3KDM4EALDH1A1BACE1 | |
| SCHEMBL20564113 | 0.95 | KMT2A (0.43) | KMT2ACASP3KDM4EALDH1A1BACE1 | |
| SCHEMBL7402885 | 0.79 | KMT2A (0.66) | KMT2ACASP3FABP7FABP5 | |
| SCHEMBL15005855 | 0.79 | CASP3 (0.48) | KMT2ACASP3BACE1 | |
| SCHEMBL7403546 | 0.75 | KMT2A (0.68) | KMT2ACASP3FABP7FABP5 | |
| SCHEMBL10149864 | 0.75 | KMT2A (0.48) | KMT2ACASP3FABP7FABP5 | |
| SCHEMBL6285024 | 0.74 | KMT2A (0.70) | KMT2ACASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2018213228-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | WDR5, MLLT1, WDR1 | KMT2A 22/4885CASP3 3562/4885KDM4E 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.